title: Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial.
abstract: To evaluate the therapeutic potential of the newly developed proton pump inhibitor lansoprazole in patients with reflux oesophagitis, we performed a double-blind randomized clinical trial comparing 20 mg omeprazole and 30 mg lansoprazole, involving 229 patients at 9 Scandinavian hospitals. The treatment period was 4 or 8 weeks, and main efficacy variables were healing of endoscopic changes, relief of reflux symptoms, and occurrence of adverse events. No significant difference in terms of healing was found, either after 4 or after 8 weeks' treatment. Patients receiving lansoprazole experienced a greater improvement in heartburn after 4 weeks (p = 0.03), and there was a similar trend for acid regurgitation. Lansoprazole was found to be an effective and safe alternative to omeprazole in short-term treatment of moderate reflux oesophagitis.
authors.affiliation: Dept. of Medicine, Haukeland University Hospital, Bergen, Norway.
authors.forename: J G
authors.initials: JG
authors.lastname: Hatlebakk
authors.forename: A
authors.initials: A
authors.lastname: Berstad
authors.forename: L
authors.initials: L
authors.lastname: Carling
authors.forename: L E
authors.initials: LE
authors.lastname: Svedberg
authors.forename: P
authors.initials: P
authors.lastname: Unge
authors.forename: P
authors.initials: P
authors.lastname: Ekström
authors.forename: L
authors.initials: L
authors.lastname: Halvorsen
authors.forename: A
authors.initials: A
authors.lastname: Stallemo
authors.forename: N
authors.initials: N
authors.lastname: Hovdenak
authors.forename: R
authors.initials: R
authors.lastname: Trondstad
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors*; D004311:Double-Blind Method; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D064747:Lansoprazole; D000251:Adenosine Triphosphatases; D009853:Omeprazole